Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California. more
Time Frame | GNLX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.58% | -2.12% | -3% |
1-Month Return | -8.84% | -3.42% | -0.73% |
3-Month Return | 2.25% | -11.13% | 2.87% |
6-Month Return | -0.44% | -5.74% | 7.17% |
1-Year Return | -82.95% | 3.97% | 25.31% |
3-Year Return | -63.09% | 1.05% | 28.38% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 11.07M | 170.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.54,"profit":true}] |
Cost of Revenue | 477.00K | 658.00K | 895.00K | 968.00K | 1.02M | [{"date":"2019-12-31","value":46.86,"profit":true},{"date":"2020-12-31","value":64.64,"profit":true},{"date":"2021-12-31","value":87.92,"profit":true},{"date":"2022-12-31","value":95.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (477.00K) | (658.00K) | (895.00K) | 10.10M | (848.00K) | [{"date":"2019-12-31","value":-4.72,"profit":false},{"date":"2020-12-31","value":-6.51,"profit":false},{"date":"2021-12-31","value":-8.86,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-8.4,"profit":false}] |
Gross Margin | - | - | - | 91.25% | (498.82%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-546.63,"profit":false}] |
Operating Expenses | 10.39M | 12.42M | 14.61M | 14.08M | 24.34M | [{"date":"2019-12-31","value":42.71,"profit":true},{"date":"2020-12-31","value":51.05,"profit":true},{"date":"2021-12-31","value":60.05,"profit":true},{"date":"2022-12-31","value":57.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (10.87M) | (12.42M) | (14.61M) | (3.01M) | (24.16M) | [{"date":"2019-12-31","value":-1087000000,"profit":false},{"date":"2020-12-31","value":-1242200000,"profit":false},{"date":"2021-12-31","value":-1461300000,"profit":false},{"date":"2022-12-31","value":-301300000,"profit":false},{"date":"2023-12-31","value":-2416500000,"profit":false}] |
Total Non-Operating Income/Expense | - | (2.44M) | (3.58M) | (2.50M) | (8.50M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-244200000,"profit":false},{"date":"2021-12-31","value":-358000000,"profit":false},{"date":"2022-12-31","value":-250200000,"profit":false},{"date":"2023-12-31","value":-849700000,"profit":false}] |
Pre-Tax Income | (11.63M) | (13.64M) | (16.38M) | (4.11M) | (28.30M) | [{"date":"2019-12-31","value":-1163100000,"profit":false},{"date":"2020-12-31","value":-1364300000,"profit":false},{"date":"2021-12-31","value":-1637800000,"profit":false},{"date":"2022-12-31","value":-410700000,"profit":false},{"date":"2023-12-31","value":-2829700000,"profit":false}] |
Income Taxes | - | 1.22M | 1.42M | 1.10M | 850.11K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":86.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.63,"profit":true},{"date":"2023-12-31","value":59.99,"profit":true}] |
Income After Taxes | - | (14.86M) | (17.80M) | (5.21M) | (29.15M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1486400000,"profit":false},{"date":"2021-12-31","value":-1779500000,"profit":false},{"date":"2022-12-31","value":-520700000,"profit":false},{"date":"2023-12-31","value":-2914710500,"profit":false}] |
Income From Continuous Operations | - | (13.64M) | (16.38M) | (5.21M) | (25.02M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1364300000,"profit":false},{"date":"2021-12-31","value":-1637800000,"profit":false},{"date":"2022-12-31","value":-520700000,"profit":false},{"date":"2023-12-31","value":-2502500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (11.63M) | (14.86M) | (17.80M) | (5.21M) | (28.30M) | [{"date":"2019-12-31","value":-1163100000,"profit":false},{"date":"2020-12-31","value":-1486400000,"profit":false},{"date":"2021-12-31","value":-1779500000,"profit":false},{"date":"2022-12-31","value":-520700000,"profit":false},{"date":"2023-12-31","value":-2829700000,"profit":false}] |
EPS (Diluted) | - | - | - | (0.40) | (1.21) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-40,"profit":false},{"date":"2023-12-31","value":-121,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
GNLX | |
---|---|
Cash Ratio | 6.13 |
Current Ratio | 6.47 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GNLX | |
---|---|
ROA (LTM) | -44.61% |
ROE (LTM) | -88.57% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GNLX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GNLX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 9454.83 |
P/B | 2.29 |
Price/FCF | NM |
EV/R | 5452.58 |
EV/Ebitda | NM |
Genelux Corporation Common Stock (GNLX) share price today is $2.27
Yes, Indians can buy shares of Genelux Corporation Common Stock (GNLX) on Vested. To buy Genelux Corporation Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GNLX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Genelux Corporation Common Stock (GNLX) via the Vested app. You can start investing in Genelux Corporation Common Stock (GNLX) with a minimum investment of $1.
You can invest in shares of Genelux Corporation Common Stock (GNLX) via Vested in three simple steps:
The 52-week high price of Genelux Corporation Common Stock (GNLX) is $16.6. The 52-week low price of Genelux Corporation Common Stock (GNLX) is $1.6.
The price-to-earnings (P/E) ratio of Genelux Corporation Common Stock (GNLX) is
The price-to-book (P/B) ratio of Genelux Corporation Common Stock (GNLX) is 2.29
The dividend yield of Genelux Corporation Common Stock (GNLX) is 0.00%
The market capitalization of Genelux Corporation Common Stock (GNLX) is $75.64M
The stock symbol (or ticker) of Genelux Corporation Common Stock is GNLX